期刊文献+

1094株革兰阴性杆菌的耐药性分析

Analysis on Resistance against Drugs of 1094 Strains of Gram Negative Bacilli
在线阅读 下载PDF
导出
摘要 目的了解革兰阴性杆菌的耐药状况,为临床用药提供参考依据。方法采用Kirby-Baure纸片扩散法,对1094株革兰阴性杆菌进行药物敏感性监测。结果1094株革兰阴性杆菌对亚胺培南、美洛培南、头孢哌酮-舒巴坦、哌拉西林-他唑巴坦敏感率依次为88.9%,87.8%,86.1%,85.0%,头孢噻吩的敏感率最低为15.2%,26.7%的大肠埃希菌和30.8%的肺炎克雷伯菌产超广谱β-内酰胺酶。结论革兰阴性杆菌除对亚胺培南、美洛培南、头孢哌酮-舒巴坦、哌拉西林-他唑巴坦有较低的抗菌活性外,对氨基糖甙类(阿米卡星,庆大霉素)、喹诺酮类(环丙沙星,左旋氧氟沙星),头孢类(一、二、三、四代)的药物均有较高的抗药性,多重耐药性细菌成为临床的主要感染菌。 Objective To realize the drug resistance of Gram negative bacilli so as to provide the reference and the foundation for clinical application of drugs. Methods Drug susceptibilities were tested in 1094 strains of Gram negative bacilli by Kirby-Baure disc diffusion. Results The drug susceptibilities of the Gram negative bacilli were 88.9% ( to imipenem) , 87.8% ( to merepenera), 86.1% (to cefoperazone/sulbactam) , 85.0% (to piperacillin/tasobactam) in succession, and the lowest susceptibility was 15.2% (to cefalotin). Furthermore, super- bread spectral β- lactamase was found in 26.7% of Escherichia coli and 30.8% of Klebsiella pneumoniae. Conclusion Gram negative bacilli possess low drug resistance against imipenem, merepenem, cefopera- zone/sulbactam and piperacillin/tasobactam, and high drug resistance against aminoglycosides ( amikacin, gentamycin), and quinolones ( ciprefloxaein, levofoxacin) and some cephalosporins.
机构地区 解放军第
出处 《临床军医杂志》 CAS 2007年第2期278-280,共3页 Clinical Journal of Medical Officers
关键词 革兰阴性杆菌 耐药性 抗菌药物 感染 gram negative bacillus drug resistance antibacterial drug infection
  • 相关文献

参考文献6

二级参考文献30

  • 1卢月梅,何林,张阮章,穆雪鵾,陈升汶.产CTX-M型超广谱β-内酰胺酶菌株的药敏试验结果分析[J].中国误诊学杂志,2004,4(7):994-996. 被引量:4
  • 2詹燏,彭少华,李从容.下呼吸道感染肠杆菌科细菌产AmpC酶和超广谱β-内酰胺酶的检测[J].中华医院感染学杂志,2004,14(7):814-816. 被引量:12
  • 3朱德妹,郭蓓宁,汪复.1992年上海地区细菌耐药性监测[J].中国抗生素杂志,1994,19(2):142-146. 被引量:57
  • 4[1]Brisse S, Milatovic D, Fluit A C. Molecular surveillance of European quinolone-resistant clinical isolates of Pseudomonas aeruginosa and Acinetobacter spp using automated ribotyping [J]. J Clin Microbiol, 2000,38 (10): 3636
  • 5[2]Afzal-Shah M, Livermore D M. Worldwide emergence of carbapenem-resistant Acinetobacter spp[J] . J Antimicrob Chemother , 1998,41:576
  • 6[3]Robert E W. Resistant mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria [J]. Clin Infect Dis, 1998,27(Suppll): S93
  • 7[4]Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain [J]. Antimicrob Agents Chemother, 2000,44(6):1556
  • 8[5]Fernandez-viladrich P, Corbella X, Corral L, et al. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumanniiwith intraventricular colistim sulfomethate sodium[J].Clin Infect Dis, 1999,28(4) :916
  • 9National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibity testing, ninth information [ S ]. Standard M100-S9. Pennsylvania: NCCLS , 1999.1.
  • 10Jacoby GA, Han P. Detection of extended-spectrun beta-lactamases incliical isolates of K lebsiella pneumoniae and Escherichia coil[J]. Journal of Clinical Microbiology,1996,34(5) :908-910.

共引文献197

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部